Continued Global Growth of Khiron's Proven
ZereniaTM Clinic Model
Focused on Patients, Physician Education and Innovation
- New clinic is in the district of Ipanema in Rio de Janeiro, a city with more than 12
million people
- Expansion into Brazil follows
Khiron´s proven and unique patient acquisition and retention
model
- 40% of Zerenia™ patient appointments in Colombia and 95% of Zerenia™ patient
appointments in the UK result in a medical cannabis
prescription
- In the initial phase of the 7,000 sq. ft. clinic,
Brazil's First Zerenia™ Clinic
will have a total capacity of approximately 23,000 patient
consults per year
- Under the leadership of Dr. Eduardo
Faveret as Medical Director, the clinic will open with more
than 13 doctors for both in-person and telehealth
models
- Brazil is Latin America's largest addressable market,
with over 210 million people
TORONTO, Aug. 9, 2022
/CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company")
(TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a global leader in medical
cannabis throughout Latin America
and Europe, is pleased to announce
the opening of Brazil's first
Zerenia™ clinic in Brazil,
Rio de Janeiro. The clinic is
located at Vinicius de Moraes 201 Ipanema, with an initial top
capacity of 23,000 patient consults per year. Khiron's
Zerenia™ Rio clinic will be the first of its kind in Brazil.
Zerenia™ Rio clinic provide physical consultations and
telehealth services, connecting patients with medical specialists
trained in the ethical, safe, and responsible prescription of
cannabinoid-based medications. These medications focus on the
comprehensive treatment of pathologies such as chronic pain,
neurological pathologies, palliative care, rheumatology,
psychiatry, geriatrics, endocrinology, gastroenterology,
gynecology, otorhinolaryngology, and dermatology.
Khiron is well positioned to expand Zerenia™ clinics in
Brazil following its successful
introduction in July 2021 of
Khiron-branded medical CBD. Dr. Eduardo
Faveret, a thought leader and innovator in medical cannabis,
has been appointed as Medical Director and will be leading the
clinic. Dr. Faveret and the Zerenia™ Rio clinic will be supported
by Khiron's strategic alliances with doctors and patient
associations, including CANNAB in Salvador
de Bahia, and leading medical distributors such as TAIMIN in
Rio de Janeiro and Sao Paulo.
"Brazil continues to experience
exponential growth in prescribing doctors and demand for medical
cannabis products by patients. ZereniaTM Rio, is
positioned as a comprehensive and humanized pioneer in patient
health service and prevention to improve the quality of life of
Brazilian families," commented Dr. Eduardo
Faveret, Medical Director for Zerenia™ Rio clinic. He
continued, "We have assembled a multidisciplinary medical team that
covers diverse medical cannabis specialties and treatments, which
makes our Zerenia™ Rio clinic unique in Brazil."
In the fall, Khiron is expected to launch additional THC medical
cannabis products in the country, which will complement its current
global portfolio.
Alvaro Torres, CEO and Director
of Khiron Life Sciences, said: "Khiron has developed a unique,
successful, and sustainable model with the implementation of
Zerenia™ in Colombia, Perú,
and the United Kingdom.
Brazil is Latin America´s largest
addressable market with more than 210 million people and we believe
that our ZereniaTM model will replicate the success we
have experienced around the world. We have served more than 25,000
individual patients across the globe through our model, with high
peer patient acquisition and retention rates. We have a fantastic
team on the ground in Brazil
composed of doctors, nurses, patient advocates, and administrative
staff in our Zerenia™ Rio clinic that will elevate our
patient-first model to new levels. Khiron's ZereniaTM
Rio clinic in Brazil will also
allow us to continue to generate more patient-based evidence on the
pharmacoeconomic benefits of our Khiron-branded medical cannabis
products, and through this data, Khiron could eventually be able
provide insurance benefits for patients as we have done in
Colombia."
About Khiron Life Sciences
Corp.
Khiron is a leading vertically integrated international medical
cannabis corporation with core operations in Latin America and Europe. Leveraging medical health clinics and
proprietary telemedicine platforms, Khiron combines a
patient-oriented approach, physician education programs,
scientific, product innovation, and cannabis operations expertise
to drive prescriptions and brand loyalty with patients worldwide.
The Company has a sales presence in Colombia, Peru, Germany, United
Kingdom, and Brazil and is
positioned to commence sales in Mexico. The Company is led by co-founder and
Chief Executive Officer, Alvaro
Torres, together with an experienced and diverse executive
team and Board of Directors.
Visit Khiron online at https://investors.khiron.ca.
Linkedin
https://www.linkedin.com/company/khiron-life-sciences-corp/
Cautionary Statement Regarding
Forward-Looking Statements
This press release may contain "forward-looking information"
within the meaning of applicable securities legislation. All
information contained herein that is not historical in nature
constitutes forward-looking information. Forward-looking
information and statements contained herein reflect management's
current beliefs and is based on information currently available and
on assumptions that management believes to be reasonable. These
assumptions include, but are not limited to, assumptions regarding
the future regulatory developments and economic conditions, the
Company's ability to continue its growth and reduce costs. The
Company undertakes no obligation to update or revise any
forward-looking information, whether as a result of new
information, estimates or opinions, future events or results or
otherwise or to explain any material difference between subsequent
actual events and such forward-looking information, except as
required by applicable law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/medical-cannabis-leader-khiron-opens-brazils-first-zerenia-clinic-301602350.html
SOURCE Khiron Life Sciences Corp.